Wells Fargo Reaffirms Their Hold Rating on Shockwave Medical (SWAV)

In a report released yesterday, Larry Biegelsen from Wells Fargo maintained a Hold rating on Shockwave Medical (SWAV – Research Report). The company’s shares closed yesterday at $287.23.

According to TipRanks, Biegelsen is a 5-star analyst with an average return of 11.5% and a 61.23% success rate. Biegelsen covers the Healthcare sector, focusing on stocks such as Abbott Labs, Bausch + Lomb Corporation, and Boston Scientific.

Shockwave Medical has an analyst consensus of Moderate Buy, with a price target consensus of $267.57.

The company has a one-year high of $315.95 and a one-year low of $157.00. Currently, Shockwave Medical has an average volume of 521.1K.

Based on the recent corporate insider activity of 108 insiders, corporate insider sentiment is neutral on the stock. Last month, Frederic Moll, a Director at SWAV bought 81,967.00 shares for a total of $49,999.87.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Shockwave Medical (SWAV) Company Description:

Shockwave Medical, Inc. operates as a medical device company. It focuses on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. The firm offers M5 catheters for treating above-the-knee peripheral artery disease; C2 catheters for treating coronary artery disease; and S4 catheters or treating below-the-knee peripheral artery disease. The company was founded by Daniel Hawkins, John M. Adams, and Todd J. Brinton in 2009 and is headquartered in Santa Clara, CA.